Correlates and characteristics of hepatitis C virus-specific T-cell immunity in exposed uninfected high-risk prison inmates

Journal of Viral Hepatitis

Volumn 20, Issue 4, 2013, Pages

  Cameron, B ^a   Galbraith, S ^a   Li, H ^a   Lloyd, A ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

cellular immunity; cytokine; exposed uninfected; hepatitis C virus; injecting drug use; seronegative

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 2; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 5A; VIRUS ANTIBODY; VIRUS RNA;

ABORIGINE; ADAPTIVE IMMUNITY; ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HEPATITIS C VIRUS; HIGH RISK POPULATION; HUMAN; IMMUNE STATUS; IN VITRO STUDY; INFECTION RISK; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; PERSISTENT INFECTION; PRIMARY INFECTION; PRIORITY JOURNAL; PRISON; SEROCONVERSION; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TATTOO; VIRAL CLEARANCE;

ADULT; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; ENVIRONMENTAL EXPOSURE; ENZYME-LINKED IMMUNOSPOT ASSAY; FEMALE; HEPACIVIRUS; HUMANS; MALE; PRISONERS; YOUNG ADULT;

EID: 84875231489     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12016     Document Type: Article

References (63)

1. Post JJ, Pan Y, Freeman AJ, et al,. Clearance of hepatitis C viremia associated with cellular immunity in the absence of seroconversion in the hepatitis C incidence and transmission in prisons study cohort. J Infect Dis 2004; 189 (10): 1846-1855.
2. Shata MT, Tricoche N, Perkus M, et al,. Exposure to low infective doses of HCV induces cellular immune responses without consistently detectable viremia or seroconversion in chimpanzees. Virology 2003; 314 (2): 601-616.
3. Koziel MJ, Wong DK, Dudley D, Houghton M, Walker BD,. Hepatitis C virus-specific cytolytic T lymphocyte and T helper cell responses in seronegative persons. J Infect Dis 1997; 176 (4): 859-866.
4. Bronowicki JP, Vetter D, Uhl G, et al,. Lymphocyte reactivity to hepatitis C virus (HCV) antigens shows evidence for exposure to HCV in HCV-seronegative spouses of HCV-infected patients. J Infect Dis 1997; 176 (2): 518-522.
5. Kamal SM, Amin A, Madwar M, et al,. Cellular immune responses in seronegative sexual contacts of acute hepatitis C patients. J Virol 2004; 78 (22): 12252-12258.
6. Scognamiglio P, Accapezzato D, Casciaro MA, et al,. Presence of effector CD8+ T cells in hepatitis C virus-exposed healthy seronegative donors. J Immunol 1999; 162 (11): 6681-6689.
7. Al-Sherbiny M, Osman A, Mohamed N, et al,. Exposure to hepatitis C virus induces cellular immune responses without detectable viremia or seroconversion. Am J Trop Med Hyg 2005; 73 (1): 44-49.
8. Freeman AJ, Ffrench RA, Post JJ, et al,. Prevalence of production of virus-specific interferon- gamma among seronegative hepatitis C-resistant subjects reporting injection drug use. J Infect Dis 2004; 190 (6): 1093-1097.
9. Mizukoshi E, Eisenbach C, Edlin BR, et al,. Hepatitis C virus (HCV)-specific immune responses of long-term injection drug users frequently exposed to HCV. J Infect Dis 2008; 198 (2): 203-212.
10. Golden-Mason L, Cox AL, Randall JA, Cheng L, Rosen HR,. Increased natural killer cell cytotoxicity and NKp30 expression protects against hepatitis C virus infection in high-risk individuals and inhibits replication in vitro. Hepatology 2010; 52: 1581-1599.
11. Waasdorp Hurtado C, Golden-Mason L, Brocato M, Krull M, Narkewicz MR, Rosen HR,. Innate Immune Function in Placenta and Cord Blood of Hepatitis C-Seropositive Mother-Infant Dyads. PLoS ONE 2010; 5 (8): e12232.
12. Thurairajah Prem H, Hegazy D, Chokshi S, et al,. Hepatitis C Virus (HCV)-Specific T Cell Responses in Injection Drug Users with Apparent Resistance to HCV Infection. J Infect Dis 2008; 198 (12): 1749-1755.
13. Knapp S, Warshow U, Ho KMA, et al,. A Polymorphism in IL28B Distinguishes Exposed, Uninfected Individuals From Spontaneous Resolvers of HCV Infection. Gastroenterology 2011; 141 (1): 320-5.e2.
14. Zeremski M, Shu MA, Brown Q, et al,. Hepatitis C virus-specific T-cell immune responses in seronegative injection drug users. J Viral Hepatitis 2009; 16 (1): 10-20.
15. Bowen DG, Walker CM,. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 2005; 436 (7053): 946-952.
16. Smyk-Pearson S, Tester IA, Klarquist J, et al,. Spontaneous recovery in acute human hepatitis C virus infection: functional T-cell thresholds and relative importance of CD4 help. J Virol 2008; 82 (4): 1827-1837.
17. Kaplan DE, Ikeda F, Li Y, et al,. Peripheral virus-specific T-cell interleukin-10 responses develop early in acute hepatitis C infection and become dominant in chronic hepatitis. J Hepatol 2008; 48 (6): 903-913.
18. Flynn JK, Dore GJ, Hellard M, et al,. Early IL-10 predominant responses are associated with progression to chronic hepatitis C virus infection in injecting drug users. J Viral Hepatitis 2011; 18 (8): 549-561.
19. Della Bella S, Riva A, Tanzi E, et al,. Hepatitis C virus-specific reactivity of CD4+-lymphocytes in children born from HCV-infected women. J Hepatol 2005; 43 (3): 394-402.
20. Teutsch S, Luciani F, Scheuer N, et al,. Incidence of primary hepatitis C infection and risk factors for transmission in an Australian prisoner cohort. BMC Public Health 2010; 10: 633.
21. Dolan K, Teutsch S, Scheuer N, et al,. Incidence and risk for acute hepatitis C infection during imprisonment in Australia. Eur J Epidemiol 2010; 25 (2): 143-148.
22. Cameron B, Bharadwaj M, Burrows J, et al,. Prolonged illness after infectious mononucleosis is associated with altered immunity but not with increased viral load. J Infect Dis 2006; 193 (5): 664-671.
23. Selin LK, Varga SM, Wong IC, Welsh RM,. Protective heterologous antiviral immunity and enhanced immunopathogenesis mediated by memory T cell populations. J Exp Med 1998; 188 (9): 1705-1715.
24. Wedemeyer H, Mizukoshi E, Davis AR, Bennink JR, Rehermann B,. Cross-reactivity between hepatitis C virus and Influenza A virus determinant-specific cytotoxic T cells. J Virol 2001; 75: 11392-11400.
25. Kennedy PT, Urbani S, Moses RA, et al,. The influence of T cell cross-reactivity on HCV-peptide specific human T cell response. Hepatology 2006; 43 (3): 602-611.
26. Neveu B, Debeaupuis E, Echasserieau K, et al,. Selection of high-avidity CD8 T cells correlates with control of hepatitis C virus infection. Hepatology 2008; 48 (3): 713-722.
27. Takaki A, Wiese M, Maertens G, et al,. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med 2000; 6 (5): 578-582.
28. Seeff LB, Hollinger FB, Alter HJ, et al,. Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: A National Heart, Lung, and Blood Institute collaborative study. Hepatology 2001; 33 (2): 455-463.
29. Rodger AJ, Roberts S, Lanigan A, Bowden S, Brown T, Crofts N,. Assessment of long-term outcomes of community-acquired hepatitis C infection in a cohort with sera stored from 1971 to 1975. Hepatology 2000; 32 (3): 582-587.
30. Blackard JT, Kemmer N, Sherman KE,. Extrahepatic replication of HCV: insights into clinical manifestations and biological consequences. Hepatology 2006; 44 (1): 15-22.
31. Sung VMH, Shimodaira S, Doughty AL, et al,. Establishment of B-cell lymphoma cell lines persistently infected with hepatitis C virus in vivo and in vitro: the apoptotic effects of virus infection. J Virol 2003; 77 (3): 2134-2146.
32. Hu Y, Shahidi A, Park S, Guilfoyle D, Hirshfield I,. Detection of extrahepatic hepatitis C virus replication by a novel, highly sensitive, single-tube nested polymerase chain reaction. Am J Clin Pathol 2003; 119 (1): 95-100.
33. Bare P, Massud I, Parodi C, et al,. Continuous release of hepatitis C virus (HCV) by peripheral blood mononuclear cells and B-lymphoblastoid cell-line cultures derived from HCV-infected patients. J Gen Virol 2005; 86 (Pt 6): 1717-1727.
34. Laporte J, Bain C, Maurel P, Inchauspe G, Agut H, Cahour A,. Differential distribution and internal translation efficiency of hepatitis C virus quasispecies present in dendritic and liver cells. Blood 2003; 101 (1): 52-57.
35. Li Y, Wang X, Douglas SD, et al,. CD8+ T cell depletion amplifies hepatitis C virus replication in peripheral blood mononuclear cells. J Infect Dis 2005; 192 (6): 1093-1101.
36. Pham TNQ, MacParland SA, Mulrooney PM, Cooksley H, Naoumov NV, Michalak TI,. Hepatitis C virus persistence after spontaneous or treatment-induced resolution of hepatitis C. J Virol 2004; 78 (11): 5867-5874.
37. Pham TNQ, Macparland SA, Coffin CS, Lee SS, Bursey FR, Michalak TI,. Mitogen-induced upregulation of hepatitis C virus expression in human lymphoid cells. J Gen Virol 2005; 3: 657-666.
38. Pham TNQ, Mulrooney-Cousins PM, Mercer SE, et al,. Antagonistic expression of hepatitis C virus and alpha interferon in lymphoid cells during persistent occult infection. J Viral Hepatitis 2007; 14 (8): 537-548.
39. Castillo I, Bartolomé J, Quiroga JA, Barril G, Carreño V,. Long-term virological follow up of patients with occult hepatitis C virus infection. Liver Int 2011; 31 (10): 1519-1524.
40. Juan AQ, Inmaculada C, Silvia L, Javier B, Guillermina B, Vicente C,. Identification of serologically silent occult hepatitis C virus infection by detecting immunoglobulin G antibody to a dominant HCV core peptide epitope. J Hepatol 2009; 50 (2): 256-263.
41. Elliott L, Lloyd A, Ziegler J, Ffrench R,. Protective immunity against hepatitis C virus infection. Immunol Cell Biol 2006; 84: 1-11.
42. Meyer MF, Lehmann M, Cornberg M, et al,. Clearance of low levels of HCV viremia in the absence of a strong adaptive immune response. Virol J 2007; 4: 58.
43. Lauer GM, Barnes E, Lucas M, et al,. High resolution analysis of cellular immune responses in resolved and persistent hepatitis C virus infection. Gastroenterology 2004; 127 (3): 924-936.
44. Neumann-Haefelin C, McKiernan S, Ward S, et al,. Dominant influence of an HLA-B27 restricted CD8+ T cell response in mediating HCV clearance and evolution. Hepatology 2006; 43 (3): 563-572.
45. Rowland-Jones SL, Dong T, Fowke KR, et al,. Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi. J Clin Invest 1998; 102 (9): 1758-1765.
46. Kaul R, Rowland-Jones SL, Kimani J, et al,. New insights into HIV-1 specific cytotoxic T-lymphocyte responses in exposed, persistently seronegative Kenyan sex workers. Immunol Lett 2001; 79 (1-2): 3-13.
47. Kaul R, Rutherford J, Rowland-Jones SL, et al,. HIV-1 Env-specific cytotoxic T-lymphocyte responses in exposed, uninfected Kenyan sex workers: a prospective analysis. AIDS 2004; 18 (15): 2087-2089.
48. Kaul R, Rowland-Jones SL, Kimani J, et al,. Late seroconversion in HIV-resistant Nairobi prostitutes despite pre-existing HIV-specific CD8+ responses.[comment]. J Clin Invest 2001; 107 (3): 341-349.
49. Cox AL, Mosbruger T, Lauer GM, Pardoll D, Thomas DL, Ray SC,. Comprehensive analyses of CD8+ T cell responses during longitudinal study of acute human hepatitis C. Hepatology 2005; 42 (1): 104-112.
50. Schulze zur Wiesch J, Lauer GM, Day CL, et al,. Broad repertoire of the CD4+ Th cell response in spontaneously controlled hepatitis C virus infection includes dominant and highly promiscuous epitopes. J Immunol 2005; 175 (6): 3603-3613.
51. Gerlach JT, Diepolder HM, Jung MC, et al,. Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C. Gastroenterology 1999; 117 (4): 933-941.
52. Netski DM, Mosbruger T, Depla E, et al,. Humoral immune response in acute hepatitis C virus infection. Clin Infect Dis 2005; 41 (5): 667-675. Epub 2005 Jul 22.
53. Accapezzato D, Francavilla V, Rawson P, et al,. Subversion of effector CD8+ T cell differentiation in acute hepatitis C virus infection: the role of the virus. Eur J Immunol 2004; 34 (2): 438-446.
54. Lechmann M, Woitas RP, Langhans B, et al,. Decreased frequency of HCV core-specific peripheral blood mononuclear cells with type 1 cytokine secretion in chronic hepatitis C. J Hepatol 1999; 31 (6): 971-978.
55. Gramenzi A, Andreone P, Loggi E, et al,. Cytokine profile of peripheral blood mononuclear cells from patients with different outcomes of hepatitis C virus infection. J Viral Hepat 2005; 12 (5): 525-530.
56. Sarih M, Bouchrit N, Benslimane A,. Different cytokine profiles of periperhal blood mononuclear cells from patients with persistent and self-limited hepatitis C virus infection. Immunol Lett 2000; 74: 117-120.
57. Tsai SL, Liaw YF, Chen MH, Huang CY, Kuo GC,. Detection of type 2-like T-helper cells in hepatitis C virus infection: implications for hepatitis C virus chronicity. Hepatology 1997; 25 (2): 449-458.
58. Kresge K,. A STEP back? Additional data released from the STEP trial raises questions about whether the vaccine may have increased the risk of HIV infection. IAVI Report The Newsletter on International AIDS Vaccine Research. 2007; http://www.iavireport.org/Issues/Issue11-5/Step.asp.
59. Kresge K,. AIDS vaccine researchers STEP up to the challenge. Questions linger, but so does determination, as researchers gather at the AIDS Vaccine 2008 Conference. IAVI Rep 2008; 12 (5): 1-7.
60. Fowke KR, Kaul R, Rosenthal KL, et al,. HIV-1-specific cellular immune responses among HIV-1-resistant sex workers. Immunol Cell Biol 2000; 78 (6): 586-595.
61. Clerici M, Giorgi JV, Chou CC, et al,. Cell-mediated immune response to human immunodeficiency virus (HIV) type 1 in seronegative homosexual men with recent sexual exposure to HIV-1. J Infect Dis 1992; 165 (6): 1012-1019.
62. Jennes W, Sawadogo S, Koblavi-Deme S, et al,. Cellular human immunodeficiency virus (HIV)-protective factors: a comparison of HIV-exposed seronegative female sex workers and female blood donors in Abidjan, Cote d'Ivoire. J Infect Dis 2003; 187 (2): 206-214.
63. Rowland-Jones SL,. Timeline: AIDS pathogenesis: what have two decades of HIV research taught us? Nat Rev Immunol 2003; 3 (4): 343-348.